Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HAEMODYNAMIC STUDIES WITH METHYLDOPA: EFFECT ON CARDIAC OUTPUT AND RESPONSE TO PRESSOR AMINES.

Literature DB >> 14063015

HAEMODYNAMIC STUDIES WITH METHYLDOPA: EFFECT ON CARDIAC OUTPUT AND RESPONSE TO PRESSOR AMINES.

C T DOLLERY, M HARINGTON, J V HODGE.

Abstract

Entities: Chemical

Keywords: ANTIHYPERTENSIVE AGENTS; HEART; NOREPINEPHRINE; PHARMACOLOGY; SEROTONIN INHIBITORS

Mesh：

Substances：

Year: 1963 PMID： 14063015 PMCID： PMC1018049 DOI： 10.1136/hrt.25.5.670

Source DB: PubMed Journal: Br Heart J ISSN： 0007-0769

× No keyword cloud information.

11 in total

1. Methyldopa in the treatment of hypertension.

Authors: R I BAYLISS; E A HARVEY-SMITH
Journal: Lancet Date: 1962-04-14 Impact factor: 79.321

2. Methyldopa in hypertension. Clinical and pharmacological studies.

Authors: C T DOLLERY; M HARINGTON
Journal: Lancet Date: 1962-04-14 Impact factor: 79.321

3. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.

Authors: L GILLESPIE; J A OATES; J R CROUT; A SJOERDSMA
Journal: Circulation Date: 1962-02 Impact factor: 29.690

4. The effects of alpha-methyl-DOPA and alpha-methyl-metatyrosine on the metabolism of norepinephrine and serotonin in vivo.

Authors: S M HESS; R H CONNAMACHER; M OZAKI; S UDENFRIEND
Journal: J Pharmacol Exp Ther Date: 1961-11 Impact factor: 4.030

5. Haemodynamic effects of guanethidine.

Authors: C T DOLLERY; D EMSLIE SMITH; J P SHILLINGFORD
Journal: Lancet Date: 1961-08-12 Impact factor: 79.321

6. The action of sympathomimetic amines in animals treated with reserpine.

Authors: J H BURN; M J RAND
Journal: J Physiol Date: 1958-12-04 Impact factor: 5.182

7. An improved method for the calibration of continuously recorded dye dilution curves.

Authors: R W EMANUEL; W W LACY; E V NEWMAN
Journal: Circ Res Date: 1957-09 Impact factor: 17.367

8. Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine.

Authors: T L SOURKES
Journal: Arch Biochem Biophys Date: 1954-08 Impact factor: 4.013

9. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine.

Authors: J A OATES; L GILLESPIE; S UDENFRIEND; A SJOERDSMA
Journal: Science Date: 1960-06-24 Impact factor: 47.728

10. Effect of alpha-methyl-3,4-dihydroxyphenylalanine (methyldopa), reserpine and related agents on some vascular responses in the dog.

Authors: C A STONE; C A ROSS; H C WENGER; C T LUDDEN; J A BLESSING; J A TOTARO; C C PORTER
Journal: J Pharmacol Exp Ther Date: 1962-04 Impact factor: 4.030

6 in total

HAEMODYNAMIC STUDIES WITH METHYLDOPA: EFFECT ON CARDIAC OUTPUT AND RESPONSE TO PRESSOR AMINES.

1. Methyldopa in the treatment of hypertension.

2. Methyldopa in hypertension. Clinical and pharmacological studies.

3. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension.

4. The effects of alpha-methyl-DOPA and alpha-methyl-metatyrosine on the metabolism of norepinephrine and serotonin in vivo.

5. Haemodynamic effects of guanethidine.

6. The action of sympathomimetic amines in animals treated with reserpine.

7. An improved method for the calibration of continuously recorded dye dilution curves.

8. Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine.

9. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine.

10. Effect of alpha-methyl-3,4-dihydroxyphenylalanine (methyldopa), reserpine and related agents on some vascular responses in the dog.

1. GUANETHIDINE AND METHYLDOPA: A HAEMODYNAMIC STUDY.

2. Effect of certain antiadrenergic agents on systolic time intervals in essential hypertension.

Review 3. Antihypertensive drugs: clinical pharmacology and therapeutic use.

4. Local anaesthetics containing vasoconstrictors.

5. Variation in the modification of cardiovascular responses by sympathetic inhibitory drugs.

6. New hypotensive drug.